( NASDAQ-NMS:RODM,OTC-BB:PROT )

News from proteonomix, inc A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Apr 01, 2013, 13:01 ET Proteonomix Settles Litigation

 Proteonomix, Inc. (OTC: PROT), a biotechnology company focused on developing therapeutics based upon the use of human cells and their...


Jan 14, 2013, 09:45 ET Proteonomix Announces Extension Of Deadline

 Proteonomix, Inc. (the "Company") (SYMBOL: PROT), a biotechnology company (the "Company") focused on developing therapeutics based upon the...


Jan 08, 2013, 09:42 ET Proteonomix Announces Restructuring

Proteonomix, Inc. (the "Company") (SYMBOL: PROT), a biotechnology company (the "Company") focused on developing therapeutics based upon the use of...


Jan 08, 2013, 09:40 ET Proteonomix Updates Status Of UMK-121 Testing

Proteonomix, Inc. (the "Company")(Symbol PROT), a biotechnology company (the "Company") focused on developing therapeutics based upon the use of...


Nov 20, 2012, 09:00 ET Proteonomix, Inc. Announces Screening of Patients with End Stage Liver Disease in its Clinical Study of UMK-121

 PROTEONOMIX, INC. (OTCBB: PROT), a biotechnology company (the "Company") focused on developing therapeutics based upon the use of human cells...


Oct 26, 2012, 09:07 ET Proteonomix, Inc. Announces Finalizing ECRF for Its Clinical Trial of UMK 121 in Patients with End Stage Liver Disease

 PROTEONOMIX, INC. (OTCBB: PROT), a biotechnology company focused on developing therapeutics based upon the use of human cells and their...


Oct 23, 2012, 09:47 ET Proteonomix, Inc. Announces Its Clinical Trial of UMK-121 in Patients with End Stage Liver Disease Has Been Listed on ClinicalTrials.gov

 PROTEONOMIX, INC. (OTCBB: PROT), a biotechnology company focused on developing therapeutics based upon the use of human cells and their...


Oct 04, 2012, 09:00 ET Proteonomix, Inc. Announces IRB Approval for Its Clinical Trial of UMK-121 in Patients with End Stage Liver Disease

 PROTEONOMIX, INC. (OTCBB: PROT), a biotechnology company focused on developing therapeutics based upon the use of human cells and their...


Mar 06, 2012, 10:44 ET Proteonomix Announces a Private Placement of $3.8 Million

 Proteonomix, Inc. (OTC/BB: PROT) announced today that it has entered into definitive agreements with certain institutional investors,...